Is a liberal arts degree useless if you want to succeed in life? Not at all.Jimmy Carter, the 39th US president, has died at 100NEW YORK (AP) — Walmart's sweeping rollback of its diversity policies is the strongest indication yet of a profound shift taking hold at U.S. companies that are revaluating the legal and political risks associated with bold programs to bolster historically underrepresented groups in business. The changes announced by the world's biggest retailer followed a string of legal victories by conservative groups that have filed an onslaught of lawsuits challenging corporate and federal programs aimed at elevating minority and women-owned businesses and employees. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Jet crash disaster in South Korea marks another setback for BoeingIt’s not hard to understand the value tight end Josh Oliver brings to the Vikings. Just listen to the way people talk about him. “He’s an animal,” tight end T.J. Hockenson said. “Once he gets his hands on somebody, it’s kind of like, ‘Good luck.'” It was similar sentiment from offensive coordinator Wes Phillips. “He’s the best blocking tight end in the league, and that’s no disrespect to anybody else,” Phillips said. “We will take Josh over anybody in this league in the role that he’s in. It’s not only that he’s physically imposing as a 270-pound man. It’s the attitude that he plays with out there.” What are the Vikings losing now that Oliver has been ruled out with an ankle injury? His absence will be felt most when the Vikings try to run the ball against the Chicago Bears on Sunday afternoon at Soldier Field. Though he has proved he can contribute in the passing game, Oliver has been a force in the running game since signing with the Vikings. There have been multiple times this season that Oliver had singlehandedly carved out space for running back Aaron Jones to go to work. That’s partially why Hockenson has played only about 50% of the offensive snaps since returning from a torn anterior cruciate ligament a few weeks ago. Even if the Vikings are often telegraphing a run when Oliver is on the field, they don’t care because they feel that strongly about his ability as a blocker. “You see it every single week,” Phillips said. “He’s moving large men and putting them on the ground.” It’s safe to assume Oliver would suit up for the Vikings if he were able to do so. He’s been playing through a wrist injury for the past few weeks, for example, and has still been extremely effective at the point of attack. How tough is it to replace Oliver in a vacuum? “It’s a big challenge because of all the things he does on a snap in and snap out basis,” head coach Kevin O’Connell said. “We will see some guys make some impacts on some different downs and distances than we have maybe seen up to this point.” Briefly The only other players on the injury report for the Vikings are tight end Nick Muse (hand) and edge rusher Gabe Murphy (knee). Both players were officially listed as questionable and being full participants in the walkthrough on Friday afternoon at TCO Performance Center.The biopharma industry is a dynamic environment. To succeed in it and thrive, companies must be innovative and must constantly re-evaluate their strategies. This will help them to navigate the challenges of drug development and entry into the market. This article provides winning strategies that can help biopharma companies stay ahead of the curve. Performing clinical trials on new drugs and making them available to patients is long, complex, and capital-demanding. To increase your chances of clinical success with a new drug pipeline, your Research and Development (R&D) efforts must be collaborative, streamlined, and effective. Invest in the R&D pipeline to maximize your organization’s opportunities for innovative therapies and minimize your risks. This might require collaboration with biotech startups, technology providers, and academic institutions to help expand your capabilities. One way that biopharma companies can boost patient’s access to investigational medication is through the use of an expanded access program. Through an Early Access Care program, biopharma companies can better understand local regulatory compassionate use pathways and new FDA legislations pertaining to investigational drugs. Such programs often work with doctors directly, helping them understand all the documentation requirements for obtaining investigational medications for patients who are not responding to conventional treatments, expediting the entire process. When a broader population of patients receives promising therapies before full approval, there is a higher potential for developing real-world data, ultimately accelerating adoption. One strategy leaders in the biopharma industry use to stay ahead of the curve is advanced data analytics and AI. Advanced analytics help deliver valuable insights by identifying biochemical pathways and technologies that could attract investor and scientific attention even before preclinical evidence is available. Biopharma companies obtain data from numerous sources, including those from clinical trials, surveys that gather patient feedback, sales data, online forums, and social media that help them better understand public sentiments. This helps them harness real-world data to predict market trends, streamline drug discovery, and optimize clinical trials, ultimately lowering development costs and improving patient outcomes. Scouting and ranking investment options using AI and advanced analytics do not replace the conventional ways of nurturing relationships through collaborations. So, you must be open to forming alliances with other leaders in the industry, healthcare providers, and contract research organizations. This creates the opportunity for sharing expertise, resources, and risks. Using advanced analytics, you can augment your approaches and widen your geographic net. To maximize the value of external assets and partnerships, you need to adopt an activist approach. Track your internal and external assets using the same rigor and evaluation metrics. Such metrics include the level of evidence, value to patients, enrollment rates, and the timely completion of trials. Doing this ensures a level playing ground when making investment decisions. Not only does this help you maximize your company’s assets, but it also helps you decide which assets to progress. To stay competitive in the biopharma industry, you must invest in workforce development and address any skill gaps promptly. This ensures that your employees are knowledgeable enough to operate innovative digital technologies emerging in their fields, promoting automation in your company’s operations. Companies that invest in reskilling their workforce can retain top talent and their business advantage while fulfilling their obligations to their employees. In addition to providing growth opportunities for your workforce, ensure that your company culture promotes diversity and innovation. Investors don’t just look at the products that are offered to them. They also look at who is offering those opportunities to them. To boost investor confidence in your company, create a credible and strong team and emphasize your track record of success and ability to steer the organization towards success. Your approach should strategically combine expert insights, transparency , and simplicity. Break down scientific jargon into easily understandable terms, showcase your strong management team, and engage with expert consultants in the field to help you build sustainable relationships with investors. Use graphics and other pictorial illustrations when showcasing your solutions to potential investors. As a biopharma company, your products must meet high safety and efficacy standards. Ensure compliance in the dynamic regulatory landscape and stay ahead of your competitors by staying updated on evolving regulations that affect your industry. Having regulatory expertise helps you streamline your development processes and effectively bring your products to the market. Ensure you engage with regulatory agencies early during your drug development process to clarify expectations and receive guidance to help you align your approach to clinical trials and submissions for approval.